Biomarkers /
LYN
Overview
LYN proto-oncogene, SRC family tyrosine kinase (LYN) is a gene that encodes a protein that functions as a protein tyrosine kinase. The protein regulates mast cell degranulation and erythroid differentiation. Missense, nonsense, and silent mutations are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.
LYN is altered in 1.26% of all cancers with breast invasive ductal carcinoma, prostate adenocarcinoma, lung adenocarcinoma, invasive breast carcinoma, and colon adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in LYN are LYN Amplification (1.15%), LYN Mutation (0.78%), LYN E110fs (0.06%), LYN Loss (0.06%), and LYN E435K (0.04%) [3].
Clinical Trials
Significance of LYN in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.